HANS JOERG NISCH / SHUTTERSTOCK.COM
There were some major IP court decisions in 2015. WIPR reflects on a busy year.
1 A song and dance over biosimilars
By now the words ‘patent dance’ should need little introduction and one of the biggest intellectual property disputes of 2015 looks likely to run into 2016.
In July, the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz that biosimilar applicants can opt out of the dance, a process allowing parties to address any patent claims while a biosimilar drug is being approved by the US Food and Drug Administration. Sandoz, which was sued by Amgen over its biosimilar version of Amgen’s drug Neupogen (filgrastim), has since launched the product.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
Supreme Court, trademark, Lindt, Fibria, FRAND, Nestle, Robin Thicke, Marvin Gaye, Eldorado, Marvel v Kimble, CJEU, Huawei v ZTE, SEP, Starbucks, Myriad,